-

Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020

SANTA CLARA, Calif--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced plans to adjourn its annual meeting of stockholders, originally scheduled to be held March 18, 2020, due to public health considerations relating to the outbreak of COVID-19 and the need to comply with federal, state and local restrictions on gatherings and movement. The annual meeting will be adjourned immediately after it is convened. As a result, stockholders should comply with the restrictions and not attend the annual meeting on March 18. Also due to the public health restrictions in place, the company will not be providing a live webcast of the meeting.

The annual meeting will be adjourned until Friday, April 17, 2020 at 8:00 a.m., Pacific Time. The record date will remain January 22, 2020.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Agilent Technologies, Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent adjourns annual shareholder meeting to April 17.
Release Versions
$Cashtags
Hashtags

Contacts

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

More News From Agilent Technologies, Inc.

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea...

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo...

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD...
Back to Newsroom